Logo image of HUMA

HUMACYTE INC (HUMA) Stock Fundamental Analysis

NASDAQ:HUMA - Nasdaq - US44486Q1031 - Common Stock - Currency: USD

2.41  -0.13 (-5.12%)

Premarket: 2.31 -0.1 (-4.15%)

Fundamental Rating

2

Taking everything into account, HUMA scores 2 out of 10 in our fundamental rating. HUMA was compared to 559 industry peers in the Biotechnology industry. HUMA has a bad profitability rating. Also its financial health evaluation is rather negative. HUMA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HUMA has reported negative net income.
HUMA had a negative operating cash flow in the past year.
HUMA had negative earnings in each of the past 5 years.
HUMA had a negative operating cash flow in each of the past 5 years.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -47.82%, HUMA is in line with its industry, outperforming 50.80% of the companies in the same industry.
With a Return On Equity value of -215.65%, HUMA is not doing good in the industry: 69.05% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -47.82%
ROE -215.65%
ROIC N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

HUMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, HUMA has more shares outstanding
Compared to 5 years ago, HUMA has more shares outstanding
Compared to 1 year ago, HUMA has an improved debt to assets ratio.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

HUMA has an Altman-Z score of -5.65. This is a bad value and indicates that HUMA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.65, HUMA is doing worse than 62.08% of the companies in the same industry.
A Debt/Equity ratio of 0.36 indicates that HUMA is not too dependend on debt financing.
HUMA has a worse Debt to Equity ratio (0.36) than 72.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z -5.65
ROIC/WACCN/A
WACCN/A
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

HUMA has a Current Ratio of 3.68. This indicates that HUMA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HUMA (3.68) is comparable to the rest of the industry.
HUMA has a Quick Ratio of 3.28. This indicates that HUMA is financially healthy and has no problem in meeting its short term obligations.
HUMA has a worse Quick ratio (3.28) than 60.64% of its industry peers.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.28
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

HUMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.00%, which is quite impressive.
EPS 1Y (TTM)31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%196.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 42.47% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 378.25% on average over the next years. This is a very strong growth
EPS Next Y74.21%
EPS Next 2Y30.92%
EPS Next 3Y29.85%
EPS Next 5Y42.47%
Revenue Next Year3628.68%
Revenue Next 2Y1827.55%
Revenue Next 3Y684.05%
Revenue Next 5Y378.25%

3.3 Evolution

HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HUMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as HUMA's earnings are expected to grow with 29.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.92%
EPS Next 3Y29.85%

More info and screens

0

5. Dividend

5.1 Amount

HUMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HUMACYTE INC

NASDAQ:HUMA (6/12/2025, 8:00:02 PM)

Premarket: 2.31 -0.1 (-4.15%)

2.41

-0.13 (-5.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners35.04%
Inst Owner Change43.67%
Ins Owners10.57%
Ins Owner Change0.31%
Market Cap373.84M
Analysts81.54
Price Target9.62 (299.17%)
Short Float %24.52%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)140.87%
Min EPS beat(2)37.25%
Max EPS beat(2)244.48%
EPS beat(4)2
Avg EPS beat(4)38.46%
Min EPS beat(4)-97.73%
Max EPS beat(4)244.48%
EPS beat(8)5
Avg EPS beat(8)17.06%
EPS beat(12)7
Avg EPS beat(12)32.88%
EPS beat(16)10
Avg EPS beat(16)34.79%
Revenue beat(2)0
Avg Revenue beat(2)-66.67%
Min Revenue beat(2)-100%
Max Revenue beat(2)-33.34%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.51%
PT rev (3m)-28.26%
EPS NQ rev (1m)6.65%
EPS NQ rev (3m)30.09%
EPS NY rev (1m)55.88%
EPS NY rev (3m)63.2%
Revenue NQ rev (1m)14.49%
Revenue NQ rev (3m)-8.27%
Revenue NY rev (1m)2.32%
Revenue NY rev (3m)-4.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 723.09
P/FCF N/A
P/OCF N/A
P/B 10.37
P/tB 10.37
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS0.23
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.82%
ROE -215.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.5%
Cap/Sales 272.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.28
Altman-Z -5.65
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.4%
Cap/Depr(5y)14.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%196.55%
EPS Next Y74.21%
EPS Next 2Y30.92%
EPS Next 3Y29.85%
EPS Next 5Y42.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year3628.68%
Revenue Next 2Y1827.55%
Revenue Next 3Y684.05%
Revenue Next 5Y378.25%
EBIT growth 1Y-6.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.92%
EBIT Next 3Y28.21%
EBIT Next 5Y25.39%
FCF growth 1Y-38.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.51%
OCF growth 3YN/A
OCF growth 5YN/A